Heart transplantation and anti-HLA antibodY: myocardial dysfunction and prognosis - HeartLAy study.
Anti-HLA antibody
Antibody-mediated rejection
Heart transplantation
Prognosis
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
29
04
2023
accepted:
08
06
2023
medline:
13
10
2023
pubmed:
7
7
2023
entrez:
7
7
2023
Statut:
ppublish
Résumé
The presence of anti-human leucocyte antigen (HLA) antibodies has been implicated in a higher incidence of complications as well as mortality rate in heart transplantation. The aim of the study was to identify through non-invasive parameters early signs of myocardial dysfunction in the presence of anti-HLA antibodies but without evidence of antibody-mediated rejection (AMR) and its possible prognostic impact. A total of 113 heart-transplanted patients without acute cellular rejection (ACR) and AMR or cardiac allograft vasculopathy (CAV) were prospectively enrolled and divided into two groups ['HLA+' (50 patients) and 'HLA-' (63 patients)], based on the presence of anti-HLA antibodies. Each patient was followed for 2 years after the enrolment, recording episodes of AMR, ACR, CAV, and mortality. Clinical characteristics were similar between the two groups. Among laboratory data, N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin values were significantly higher in the presence of anti-HLA antibodies (P < 0.001 and P = 0.003, respectively). The echocardiographic parameters that showed a statistically significant difference between the two groups were deceleration time of E wave (DecT E, P < 0.001), left ventricular global longitudinal strain (P < 0.001), tricuspid annular plane systolic excursion (P = 0.011), tricuspid S' wave (P = 0.002), and free wall right ventricular longitudinal strain (fwRVLS, P = 0.027), whereas left atrial strain did not differ significantly (P = 0.408). Univariate analysis showed that anti-HLA antibodies were associated with the development of CAV at both 1 and 2 year follow-up [odds ratio (OR) 11.90, 95% confidence interval (CI) 1.43-90.79, P = 0.022 and OR 3.37, 95% CI 1.78-9.67, P = 0.024, respectively]. Bivariate analysis demonstrated that both fwRVLS and DecT E were predictors of CAV development independently from HLA status. The presence of circulating anti-HLA antibodies is correlated with a mild cardiac dysfunction, even in the absence of AMR, and CAV development. Interestingly, reduced values of DecT E and fwRVLS were predictors of future development of CAV, independently from anti-HLA antibody.
Identifiants
pubmed: 37415291
doi: 10.1002/ehf2.14442
pmc: PMC10567642
doi:
Substances chimiques
Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2853-2864Informations de copyright
© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Am J Transplant. 2011 Feb;11(2):312-9
pubmed: 21219570
Eur Heart J Cardiovasc Imaging. 2015 Sep;16(9):919-48
pubmed: 26139361
J Am Soc Echocardiogr. 2018 Mar;31(3):349-360
pubmed: 29275986
JACC Cardiovasc Imaging. 2010 Oct;3(10):989-1000
pubmed: 20947044
J Heart Lung Transplant. 2017 May;36(5):567-576
pubmed: 28089194
J Transplant. 2013;2013:519680
pubmed: 23984043
ESC Heart Fail. 2023 Oct;10(5):2853-2864
pubmed: 37415291
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
J Am Coll Cardiol. 2007 Sep 11;50(11):1064-9
pubmed: 17825716
JACC Cardiovasc Imaging. 2018 Oct;11(10):1514-1530
pubmed: 30286911
J Heart Lung Transplant. 2010 Jul;29(7):717-27
pubmed: 20620917
J Am Soc Echocardiogr. 2015 Oct;28(10):1149-56
pubmed: 26165446
J Heart Lung Transplant. 2013 Dec;32(12):1147-62
pubmed: 24263017
Heart Fail Rev. 2021 Mar;26(2):319-336
pubmed: 32889634
J Heart Lung Transplant. 2016 Feb;35(2):179-85
pubmed: 26520246
J Heart Lung Transplant. 2018 May;37(5):537-547
pubmed: 29452978
Circulation. 2015 May 5;131(18):1608-39
pubmed: 25838326
Curr Opin Organ Transplant. 2019 Jun;24(3):245-251
pubmed: 31090631
J Heart Lung Transplant. 2017 May;36(5):540-545
pubmed: 27916323
Cardiovasc Ultrasound. 2009 Feb 08;7:6
pubmed: 19200402
Int J Cardiovasc Imaging. 2021 May;37(5):1621-1628
pubmed: 33442856
Echocardiography. 2020 Apr;37(4):561-569
pubmed: 32200582
J Heart Lung Transplant. 1995 Sep-Oct;14(5):856-64
pubmed: 8800720
Transpl Int. 2016 Jan;29(1):63-72
pubmed: 26340387
Transplant Proc. 2002 Sep;34(6):2174-7
pubmed: 12270355
J Am Soc Echocardiogr. 2020 Sep;33(9):1132-1140.e2
pubmed: 32653298
Exp Clin Transplant. 2008 Sep;6(3):229-35
pubmed: 18954302
Cardiovasc Ultrasound. 2021 Jan 9;19(1):6
pubmed: 33422079
Trends Mol Med. 2015 May;21(5):319-29
pubmed: 25801125
J Heart Lung Transplant. 2006 Feb;25(2):153-9
pubmed: 16446213
Clin Transplant. 1996 Dec;10(6 Pt 2):639-45
pubmed: 8996758